BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46:479-493. [PMID: 28707337 DOI: 10.1111/apt.14201] [Cited by in Crossref: 317] [Cited by in F6Publishing: 340] [Article Influence: 63.4] [Reference Citation Analysis]
Number Citing Articles
1 Hyun J, Lee SK, Cheon JH, Yong DE, Koh H, Kang YK, Kim MH, Sohn Y, Cho Y, Baek YJ, Kim JH, Ahn JY, Jeong SJ, Yeom JS, Choi JY. Faecal microbiota transplantation reduces amounts of antibiotic resistance genes in patients with multidrug-resistant organisms. Antimicrob Resist Infect Control 2022;11:20. [DOI: 10.1186/s13756-022-01064-4] [Reference Citation Analysis]
2 Buddle JE, Fagan RP. Pathogenicity and virulence of Clostridioides difficile. Virulence 2022. [DOI: 10.1080/21505594.2022.2150452] [Reference Citation Analysis]
3 Melamed E, Palmer JL, Fonken C. Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis. Front Mol Neurosci 2022;15. [DOI: 10.3389/fnmol.2022.1019877] [Reference Citation Analysis]
4 Bogatic D, Bryant RV, Lynch KD, Costello SP. Microbial manipulation as therapy for primary sclerosing cholangitis. Aliment Pharmacol Ther 2022. [DOI: 10.1111/apt.17251] [Reference Citation Analysis]
5 Lee EH, Lee SK, Cheon JH, Koh H, Lee JA, Kim CH, Kim J, Lee KH, Lee SJ, Kim JH, Ahn JY, Jeong SJ, Ku NS, Yong D, Yoon SS, Yeom J, Choi JY. Comparing the efficacy of different methods of faecal microbiota transplantation via oral capsule, oesophagogastroduodenoscopy, colonoscopy, or gastric tube. Journal of Hospital Infection 2022. [DOI: 10.1016/j.jhin.2022.11.007] [Reference Citation Analysis]
6 Piccioni A, Rosa F, Manca F, Pignataro G, Zanza C, Savioli G, Covino M, Ojetti V, Gasbarrini A, Franceschi F, Candelli M. Gut Microbiota and Clostridium difficile: What We Know and the New Frontiers. IJMS 2022;23:13323. [DOI: 10.3390/ijms232113323] [Reference Citation Analysis]
7 Ma J, Chen T, Ma X, Zhang B, Zhang J, Xu L, Wang Y, Huang J, Liu Z, Wang F, Tang X. Comprehensive bibliometric and visualized analysis of research on fecal microbial transplantation published from 2000 to 2021. BioMed Eng OnLine 2022;21:78. [DOI: 10.1186/s12938-022-01046-y] [Reference Citation Analysis]
8 Svensson CK, Cold F, Ribberholt I, Zangenberg M, Mirsepasi-lauridsen HC, Petersen AM, Helms M. The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent Clostridioides difficile Infection: A Retrospective Cohort Study. Cells 2022;11:3272. [DOI: 10.3390/cells11203272] [Reference Citation Analysis]
9 Dogra S, Oneto C, Sherman A, Varughese R, Yuen A, Sherman I, Cohen A, Luo Y, Chen LA. Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for C. difficile Infections Across Academic and Private Clinical Settings. J Clin Gastroenterol 2022. [PMID: 36227005 DOI: 10.1097/MCG.0000000000001778] [Reference Citation Analysis]
10 Hamblin H, Gunaratne AW, Clancy A, Pilarinos D, Lebusque A, Dawson MVM, Borody TJ, Day A. Pre-Antibiotic Treatment Followed by Prolonged Repeated Faecal Microbiota Transplantation Improves Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome: An Observational Australian Clinical Experience. Gastroenterology Research and Practice 2022;2022:1-17. [DOI: 10.1155/2022/6083896] [Reference Citation Analysis]
11 Kempski J, Huber S. Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen. Innere Medizin 2022;63:1022-1027. [DOI: 10.1007/s00108-022-01396-8] [Reference Citation Analysis]
12 Lv L, Ruan G, Ping Y, Cheng Y, Tian Y, Xiao Z, Zhao X, Chen D, Wei Y. Clinical study on sequential treatment of severe diarrhea irritable bowel syndrome with precision probiotic strains transplantation capsules, fecal microbiota transplantation capsules and live combined bacillus subtilis and enterococcus faecium capsules. Front Cell Infect Microbiol 2022;12:1025889. [DOI: 10.3389/fcimb.2022.1025889] [Reference Citation Analysis]
13 Nigam M, Panwar AS, Singh RK. Orchestrating the fecal microbiota transplantation: Current technological advancements and potential biomedical application. Front Med Technol 2022;4. [DOI: 10.3389/fmedt.2022.961569] [Reference Citation Analysis]
14 Wang N, Fang J. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. Trends in Microbiology 2022. [DOI: 10.1016/j.tim.2022.08.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Marino D, Kelly CR. Annals for Hospitalists Inpatient Notes - Clinical Pearls-Updates on Clostridioides difficile Infection for Hospitalists. Ann Intern Med 2022;175:HO2-3. [PMID: 36122397 DOI: 10.7326/M22-2266] [Reference Citation Analysis]
16 Allegretti JR. Should faecal microbiota transplantation be used earlier in the treatment framework? The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00301-6] [Reference Citation Analysis]
17 Thandavaram A, Channar A, Purohit A, Shrestha B, Patel D, Shah H, Hanna K, Kaur H, Alazzeh MS, Mohammed L. The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.27979] [Reference Citation Analysis]
18 Koopman N, van Leeuwen P, Brul S, Seppen J. History of fecal transplantation; camel feces contains limited amounts of Bacillus subtilis spores and likely has no traditional role in the treatment of dysentery. PLoS ONE 2022;17:e0272607. [DOI: 10.1371/journal.pone.0272607] [Reference Citation Analysis]
19 Trivedi R, Upadhyay TK, Kausar MA, Saeed A, Sharangi AB, Almatroudi A, Alabdallah NM, Saeed M, Aqil F. Nanotechnological interventions of the microbiome as a next-generation antimicrobial therapy. Sci Total Environ 2022;833:155085. [PMID: 35398124 DOI: 10.1016/j.scitotenv.2022.155085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Nishida A, Nishino K, Ohno M, Sakai K, Owaki Y, Noda Y, Imaeda H. Update on gut microbiota in gastrointestinal diseases. WJCC 2022;10:7653-64. [DOI: 10.12998/wjcc.v10.i22.7653] [Reference Citation Analysis]
21 Tian B, Zhang Y, Deng C, Guo C. Efficacy of Probiotic Consortium Transplantation on Experimental Necrotizing Enterocolitis. J Surg Res 2022;279:598-610. [PMID: 35926310 DOI: 10.1016/j.jss.2022.05.030] [Reference Citation Analysis]
22 Konturek PC, Hess T, Dieterich W, Zopf Y. Fecal Microbiota Transplantation for Microbiome Modulation: A Clinical View. Principles in Microbiome Engineering 2022. [DOI: 10.1002/9783527825462.ch8] [Reference Citation Analysis]
23 Qiu J, Wu C, Gao Q, Li S, Li Y. Effect of fecal microbiota transplantation on the TGF-β1/Smad signaling pathway in rats with TNBS-induced colitis. Ann Transl Med 2022;10:825. [PMID: 36034975 DOI: 10.21037/atm-22-3227] [Reference Citation Analysis]
24 Haifer C, Luu LDW, Paramsothy S, Borody TJ, Leong RW, Kaakoush NO. Microbial determinants of effective donors in faecal microbiota transplantation for UC. Gut 2022:gutjnl-2022-327742. [PMID: 35879048 DOI: 10.1136/gutjnl-2022-327742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Peixoto RS, Voolstra CR, Sweet M, Duarte CM, Carvalho S, Villela H, Lunshof JE, Gram L, Woodhams DC, Walter J, Roik A, Hentschel U, Thurber RV, Daisley B, Ushijima B, Daffonchio D, Costa R, Keller-Costa T, Bowman JS, Rosado AS, Reid G, Mason CE, Walke JB, Thomas T, Berg G. Harnessing the microbiome to prevent global biodiversity loss. Nat Microbiol 2022. [PMID: 35864220 DOI: 10.1038/s41564-022-01173-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Yang L, Li W, Zhang X, Tian J, Ma X, Han L, Wei H, Meng W. The evaluation of different types fecal bacteria products for the treatment of recurrent Clostridium difficile associated diarrhea: A systematic review and network meta-analysis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.927970] [Reference Citation Analysis]
27 Leonardi I. Beyond the gut. Science 2022;377:165-165. [DOI: 10.1126/science.abq6056] [Reference Citation Analysis]
28 Li X, Xiao F, Li Y, Hu H, Xiao Y, Xu Q, Li D, Yu G, Wang Y, Zhang T. Characteristics and management of children with Clostridioides difficile infection at a tertiary pediatric hospital in China. The Brazilian Journal of Infectious Diseases 2022;26:102380. [DOI: 10.1016/j.bjid.2022.102380] [Reference Citation Analysis]
29 Li Q, Zhou S, Wang Y, Cong J. Changes of intestinal microbiota and microbiota-based treatments in IBD. Arch Microbiol 2022;204:442. [PMID: 35776212 DOI: 10.1007/s00203-022-03069-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Rakotonirina A, Galperine T, Allémann E. Fecal microbiota transplantation: a review on current formulations in Clostridioides difficile infection and future outlooks. Expert Opin Biol Ther 2022. [PMID: 35763604 DOI: 10.1080/14712598.2022.2095901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Qu Z, Tian P, Yang B, Zhao J, Wang G, Chen W. Fecal microbiota transplantation for diseases: Therapeutic potential, methodology, risk management in clinical practice. Life Sci 2022;304:120719. [PMID: 35716734 DOI: 10.1016/j.lfs.2022.120719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
32 Shaheen WA, Quraishi MN, Iqbal TH. Gut microbiome and autoimmune disorders. Clin Exp Immunol 2022:uxac057. [PMID: 35652460 DOI: 10.1093/cei/uxac057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Facciotti F. Modulation of intestinal immune cell responses by eubiotic or dysbiotic microbiota in inflammatory bowel diseases. PharmaNutrition 2022. [DOI: 10.1016/j.phanu.2022.100303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zhao H, Zhang X, Zhang N, Yan B, Xu K, Peng L, Pan F. Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials. Front Nutr 2022;9:890357. [DOI: 10.3389/fnut.2022.890357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Vendrik KE, Bekker-chernova VO, Kuijper EJ, Terveer EM, van Hilten JJ, Contarino MF. Safety and feasibility of fecal microbiota transplantation for Parkinson’s disease patients: a protocol for a self-controlled interventional donor-FMT pilot study.. [DOI: 10.1101/2022.05.23.22274942] [Reference Citation Analysis]
36 Caira-Chuquineyra B, Fernandez-Guzman D, Soriano-Moreno DR, Fernandez-Morales J, Flores-Lovon K, Medina-Ramírez SA, Gonzales-Uribe AG, Pelayo-Luis IP, Gonzales-Zamora JA, Huaringa-Marcelo J. Fecal Microbiota Transplantation for People Living with Human Immunodeficiency Virus: A Scoping Review. AIDS Res Hum Retroviruses 2022. [PMID: 35451337 DOI: 10.1089/AID.2022.0016] [Reference Citation Analysis]
37 Kunishima H, Ohge H, Suzuki H, Nakamura A, Matsumoto K, Mikamo H, Mori N, Morinaga Y, Yanagihara K, Yamagishi Y, Yoshizawa S. Japanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection. J Infect Chemother 2022:S1341-321X(21)00347-0. [PMID: 35618618 DOI: 10.1016/j.jiac.2021.12.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Liu M, Zhong P. Modulating the Gut Microbiota as a Therapeutic Intervention for Alzheimer’s Disease. Indian J Microbiol. [DOI: 10.1007/s12088-022-01025-w] [Reference Citation Analysis]
39 Takáčová M, Bomba A, Tóthová C, Micháľová A, Turňa H. Any Future for Faecal Microbiota Transplantation as a Novel Strategy for Gut Microbiota Modulation in Human and Veterinary Medicine? Life 2022;12:723. [DOI: 10.3390/life12050723] [Reference Citation Analysis]
40 Miyauchi E, Shimokawa C, Steimle A, Desai MS, Ohno H. The impact of the gut microbiome on extra-intestinal autoimmune diseases. Nat Rev Immunol. [DOI: 10.1038/s41577-022-00727-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
41 Pérez-Nadales E, Cano Á, Recio M, Artacho MJ, Guzmán-Puche J, Doblas A, Vidal E, Natera C, Martínez-Martínez L, Torre-Cisneros J, Castón JJ. Randomised, double-blind, placebo-controlled, phase 2, superiority trial to demonstrate the effectiveness of faecal microbiota transplantation for selective intestinal decolonisation of patients colonised by carbapenemase-producing Klebsiella pneumoniae (KAPEDIS). BMJ Open 2022;12:e058124. [PMID: 35387830 DOI: 10.1136/bmjopen-2021-058124] [Reference Citation Analysis]
42 Macareño-castro J, Solano-salazar A, Dong LT, Mohiuddin M, Espinoza JL. Fecal microbiota transplantation for Carbapenem-Resistant Enterobacteriaceae: A systematic review. Journal of Infection 2022. [DOI: 10.1016/j.jinf.2022.04.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Groenewegen B, van Lingen E, Ooijevaar RE, Wessels E, Feltkamp MCW, Boeije-koppenol E, Verspaget HW, Kuijper EJ, van Prehn J, Keller JJ, Terveer EM, on behalf of the Study Group of the Netherlands Donor Feces Bank. How to prepare stool banks for an appropriate response to the ongoing COVID-19 pandemic: Experiences in the Netherlands and a retrospective comparative cohort study for faecal microbiota transplantation. PLoS ONE 2022;17:e0265426. [DOI: 10.1371/journal.pone.0265426] [Reference Citation Analysis]
44 Strati F, Lattanzi G, Amoroso C, Facciotti F. Microbiota-targeted therapies in inflammation resolution. Semin Immunol 2022;:101599. [PMID: 35304068 DOI: 10.1016/j.smim.2022.101599] [Reference Citation Analysis]
45 Abdureyim Z, Wang L, Tao Q, Xu J, Yimiti D, Gao Q, Khalaf OI. Bachu Mushroom Polysaccharide Alleviates Colonic Injury by Modulating the Gut Microbiota. Computational and Mathematical Methods in Medicine 2022;2022:1-12. [DOI: 10.1155/2022/1353724] [Reference Citation Analysis]
46 Núñez F. P, Quera R, Bay C, Thomson P. Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases. Gastroenterología y Hepatología (English Edition) 2022;45:223-230. [DOI: 10.1016/j.gastre.2021.05.005] [Reference Citation Analysis]
47 Kelly CR, Fischer M, Allegretti JR, Laplante K, Stewart DB, Limketkai BN, Stollman N. Response to McFarland et al. Am J Gastroenterol 2022;117:501-502. [DOI: 10.14309/ajg.0000000000001638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wu J, Lv L, Wang C. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials. Front Cell Infect Microbiol 2022;12:827395. [DOI: 10.3389/fcimb.2022.827395] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
49 Cibulková I, Řehořová V, Duška F. Importance of intestinal microbiota in critically ill patients and possibilities of its influence. Anest intenziv Med 2022;33:32-38. [DOI: 10.36290/aim.2022.003] [Reference Citation Analysis]
50 Metwaly A, Reitmeier S, Haller D. Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders. Nat Rev Gastroenterol Hepatol. [DOI: 10.1038/s41575-022-00581-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
51 Zhang X, Ishikawa D, Nomura K, Fukuda N, Haraikawa M, Haga K, Shibuya T, Mita T, Nagahara A. Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis. J Clin Med 2022;11:1055. [PMID: 35207328 DOI: 10.3390/jcm11041055] [Reference Citation Analysis]
52 Mccoubrey LE, Elbadawi M, Basit AW. Current clinical translation of microbiome medicines. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Gweon TG, Lee YJ, Kim KO, Yim SK, Soh JS, Kim SY, Park JJ, Shin SY, Lee TH, Choi CH, Cho YS, Yong D, Chung JW, Lee KJ, Lee OY, Choi MG, Choi M; Gut Microbiota and Therapy Research Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea. J Neurogastroenterol Motil 2022;28:28-42. [PMID: 34980687 DOI: 10.5056/jnm21221] [Reference Citation Analysis]
54 Sannathimmappa MB, Nambiar V, Aravindakshan R. Antibiotics at the crossroads - Do we have any therapeutic alternatives to control the emergence and spread of antimicrobial resistance? J Educ Health Promot 2021;10:438. [PMID: 35071644 DOI: 10.4103/jehp.jehp_557_21] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
55 Isidori M, Corbee RJ, Trabalza-marinucci M. Nonpharmacological Treatment Strategies for the Management of Canine Chronic Inflammatory Enteropathy—A Narrative Review. Veterinary Sciences 2022;9:37. [DOI: 10.3390/vetsci9020037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Nibbering B, Gerding DN, Kuijper EJ, Zwittink RD, Smits WK. Host Immune Responses to Clostridioides difficile: Toxins and Beyond. Front Microbiol. 2021;12:804949. [PMID: 34992590 DOI: 10.3389/fmicb.2021.804949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
57 Sandhu A, Chopra T. Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol 2021;14:17562848211053105. [PMID: 34992678 DOI: 10.1177/17562848211053105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
58 Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne) 2021;8:765474. [PMID: 34988090 DOI: 10.3389/fmed.2021.765474] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
59 Szychowiak P, Villageois-Tran K, Patrier J, Timsit JF, Ruppé É. The role of the microbiota in the management of intensive care patients. Ann Intensive Care 2022;12:3. [PMID: 34985651 DOI: 10.1186/s13613-021-00976-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
60 Giles J, Roberts A. Clostridioides difficile: Current overview and future perspectives. Immunotherapeutics 2022. [DOI: 10.1016/bs.apcsb.2021.11.003] [Reference Citation Analysis]
61 Radhakrishanan A, Kakkar P, Tandon C, Srivastav R. Fecal Microbiome Transplantation: An Offhand Recipe for Microbiome Therapeutics. Comprehensive Gut Microbiota 2022. [DOI: 10.1016/b978-0-12-819265-8.00001-2] [Reference Citation Analysis]
62 Pratap Mouli V, Ahuja V. Microbiota Based Management of the Gastrointestinal Disorders. Comprehensive Gut Microbiota 2022. [DOI: 10.1016/b978-0-12-819265-8.00011-5] [Reference Citation Analysis]
63 Brun P, Castagliuolo I. Antimicrobial Treatments of Infectious Diarrhea. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00069-4] [Reference Citation Analysis]
64 Davidovics Z, Wilschanski M. Cystic Fibrosis. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition 2022. [DOI: 10.1007/978-3-030-80068-0_41] [Reference Citation Analysis]
65 Seekatz AM, Safdar N, Khanna S. The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol 2022;15:175628482211343. [DOI: 10.1177/17562848221134396] [Reference Citation Analysis]
66 Penney J, Wick J, Basein T, Doron S. C. difficile Microbiome Manipulation. Infection Prevention 2022. [DOI: 10.1007/978-3-030-98427-4_16] [Reference Citation Analysis]
67 Pant A, Das B. Microbiome-based therapeutics: Opportunity and challenges. Progress in Molecular Biology and Translational Science 2022. [DOI: 10.1016/bs.pmbts.2022.07.006] [Reference Citation Analysis]
68 Meštrović T, Patterson J. Human Microbiome and Disease. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00145-2] [Reference Citation Analysis]
69 Tulli G, Maria ZG. The Microbiome in Critically Ill Patients. Practical Trends in Anesthesia and Intensive Care 2020-2021 2022. [DOI: 10.1007/978-3-031-14612-1_7] [Reference Citation Analysis]
70 Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, Qin K, Hu Z, Yang M, Lu F, Ye Q. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Front Med (Lausanne) 2021;8:766126. [PMID: 34966755 DOI: 10.3389/fmed.2021.766126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
71 Hollingshead C, Ciricillo J, Kammeyer J. Ethical Implications of the Fecal Microbiota Transplantation: Disclosure of a False-Positive HIV Test. Case Rep Infect Dis 2021;2021:6696542. [PMID: 34912583 DOI: 10.1155/2021/6696542] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Popa D, Neamtu B, Mihalache M, Boicean A, Banciu A, Banciu DD, Moga DFC, Birlutiu V. Fecal Microbiota Transplant in Severe and Non-Severe Clostridioides difficile Infection. Is There a Role of FMT in Primary Severe CDI? J Clin Med 2021;10:5822. [PMID: 34945118 DOI: 10.3390/jcm10245822] [Reference Citation Analysis]
73 Parnell JM, Nicholson MR, Kellermayer R, Kahn SA. Pediatric Fecal Microbiota Transplantation in Recurrent Clostridioides Difficile. Pediatr Ann 2021;50:e515-21. [PMID: 34889135 DOI: 10.3928/19382359-20211111-01] [Reference Citation Analysis]
74 Valeri F, dos Santos Guilherme M, He F, Stoye NM, Schwiertz A, Endres K. Impact of the Age of Cecal Material Transfer Donors on Alzheimer’s Disease Pathology in 5xFAD Mice. Microorganisms 2021;9:2548. [DOI: 10.3390/microorganisms9122548] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
75 Abbas N, Quraishi MN, Trivedi P. Emerging drugs for the treatment of primary sclerosing cholangitis. Curr Opin Pharmacol 2021;62:23-35. [PMID: 34894541 DOI: 10.1016/j.coph.2021.11.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
76 Chen HL, Zeng YB, Zhang ZY, Kong CY, Zhang SL, Li ZM, Huang JT, Xu YY, Mao YQ, Cai PR, Han B, Wang WQ, Wang LS. Gut and Cutaneous Microbiome Featuring Abundance of Lactobacillus reuteri Protected Against Psoriasis-Like Inflammation in Mice. J Inflamm Res 2021;14:6175-90. [PMID: 34853526 DOI: 10.2147/JIR.S337031] [Reference Citation Analysis]
77 Applications of Microbial Fermentation to Food Products, Chemicals and Pharmaceuticals. Advanced Fermentation and Cell Technology 2021. [DOI: 10.1002/9781119042792.part2] [Reference Citation Analysis]
78 Bernard R, Hourigan SK, Nicholson MR. Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients. J Pediatric Infect Dis Soc 2021;10:S58-63. [PMID: 34791396 DOI: 10.1093/jpids/piab056] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
79 Yadav M, Chauhan NS. Microbiome therapeutics: exploring the present scenario and challenges. Gastroenterology Report 2021. [DOI: 10.1093/gastro/goab046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
80 Chen CC, Chiu CH. Current and future applications of fecal microbiota transplantation for children. Biomed J 2021:S2319-4170(21)00153-0. [PMID: 34781002 DOI: 10.1016/j.bj.2021.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
81 Waller KMJ, Leong RW, Paramsothy S. An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases. J Gastroenterol Hepatol 2021. [PMID: 34735024 DOI: 10.1111/jgh.15731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
82 Tian JS. A review of Colorectal Cancer and Intestinal Microbiota. 2021 10th International Conference on Bioinformatics and Biomedical Science 2021. [DOI: 10.1145/3498731.3498757] [Reference Citation Analysis]
83 Burstiner LS, Silver J, Burstiner LJ, Teymoorian A, Pallav K, Jones D, Owings A, Glover S. Escherichia coli O157: H7 sepsis following fecal microbiota transplant in an IgA-deficient inflammatory bowel disease patient. Gastroenterology Report 2021. [DOI: 10.1093/gastro/goab041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Al-Ali D, Ahmed A, Shafiq A, McVeigh C, Chaari A, Zakaria D, Bendriss G. Fecal microbiota transplants: A review of emerging clinical data on applications, efficacy, and risks (2015-2020). Qatar Med J 2021;2021:5. [PMID: 34604008 DOI: 10.5339/qmj.2021.5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Cibulková I, Řehořová V, Hajer J, Duška F. Fecal Microbial Transplantation in Critically Ill Patients-Structured Review and Perspectives. Biomolecules 2021;11:1459. [PMID: 34680092 DOI: 10.3390/biom11101459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Wolter M, Grant ET, Boudaud M, Steimle A, Pereira GV, Martens EC, Desai MS. Leveraging diet to engineer the gut microbiome. Nat Rev Gastroenterol Hepatol 2021;18:885-902. [PMID: 34580480 DOI: 10.1038/s41575-021-00512-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 20.0] [Reference Citation Analysis]
87 Stojek M, Jabłońska A, Adrych K. The Role of Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease. J Clin Med 2021;10:4055. [PMID: 34575166 DOI: 10.3390/jcm10184055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Opoku-Acheampong I, McLaud T, Anderson OS. Fecal Microbiota Transplantation to Prevent and Treat Chronic Disease: Implications for Dietetics Practice. J Acad Nutr Diet 2022;122:33-7. [PMID: 34487914 DOI: 10.1016/j.jand.2021.08.112] [Reference Citation Analysis]
89 Nana T, Moore C, Boyles T, Brink AJ, Cleghorn J, Devenish LM, du Toit B, Fredericks ES, Lekalakala-Mokaba MR, Maluleka C, Rajabally MN, Reubenson G, Shuping L, Swart K, Swe Han KS, Wadula J, Wojno J, Lowman W. South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline. S Afr J Infect Dis 2020;35:219. [PMID: 34485483 DOI: 10.4102/sajid.v35i1.219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Cold F, Baunwall SMD, Dahlerup JF, Petersen AM, Hvas CL, Hansen LH. Systematic review with meta-analysis: encapsulated faecal microbiota transplantation - evidence for clinical efficacy. Therap Adv Gastroenterol 2021;14:17562848211041004. [PMID: 34484424 DOI: 10.1177/17562848211041004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
91 Min Q, Yang J, Gong X. The Use of a Three-in-One Practice-Management-Innovation Training Model in the Construction of an Infection Control Team. Risk Manag Healthc Policy 2021;14:3403-9. [PMID: 34429671 DOI: 10.2147/RMHP.S319155] [Reference Citation Analysis]
92 Tamilarasan AG, Krishnananthan T. Faecal microbiota transplantation: what's beyond Clostridium difficile infection? Eur J Gastroenterol Hepatol 2021;33:487-94. [PMID: 33177380 DOI: 10.1097/MEG.0000000000001938] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
93 Zheng SY, Li HX, Xu RC, Miao WT, Dai MY, Ding ST, Liu HD. Potential roles of gut microbiota and microbial metabolites in Parkinson's disease. Ageing Res Rev 2021;69:101347. [PMID: 33905953 DOI: 10.1016/j.arr.2021.101347] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
94 Cho YS. Fecal Microbiota Transplantation Is Effective for the Treatment of Partially Treated Clostridioides difficile Infection. Gut Liver 2021;15:1-2. [PMID: 33443235 DOI: 10.5009/gnl20368] [Reference Citation Analysis]
95 Moreira-Rosário A, Marques C, Pinheiro H, Araújo JR, Ribeiro P, Rocha R, Mota I, Pestana D, Ribeiro R, Pereira A, de Sousa MJ, Pereira-Leal J, de Sousa J, Morais J, Teixeira D, Rocha JC, Silvestre M, Príncipe N, Gatta N, Amado J, Santos L, Maltez F, Boquinhas A, de Sousa G, Germano N, Sarmento G, Granja C, Póvoa P, Faria A, Calhau C. Gut Microbiota Diversity and C-Reactive Protein Are Predictors of Disease Severity in COVID-19 Patients. Front Microbiol 2021;12:705020. [PMID: 34349747 DOI: 10.3389/fmicb.2021.705020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 21.0] [Reference Citation Analysis]
96 Feuerstadt P, Aroniadis OC, Svedlund FL, Garcia M, Stong L, Boules M, Khanna S. Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection. Dig Dis Sci 2021. [PMID: 34275058 DOI: 10.1007/s10620-021-07141-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
97 Zhu F, Ke Y, Luo Y, Wu J, Wu P, Ma F, Liu Y. Effects of Different Treatment of Fecal Microbiota Transplantation Techniques on Treatment of Ulcerative Colitis in Rats. Front Microbiol 2021;12:683234. [PMID: 34335508 DOI: 10.3389/fmicb.2021.683234] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
98 Chande N, Costello SP, Limketkai BN, Parker CE, Nguyen TM, Macdonald JK, Feagan BG. Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews. Inflamm Bowel Dis 2020;26:843-51. [PMID: 31560744 DOI: 10.1093/ibd/izz223] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
99 Du C, Luo Y, Walsh S, Grinspan A. Oral Fecal Microbiota Transplant Capsules Are Safe and Effective for Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2021;55:300-8. [PMID: 33471490 DOI: 10.1097/MCG.0000000000001495] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
100 Bar-Yoseph H, Carasso S, Shklar S, Korytny A, Even Dar R, Daoud H, Nassar R, Maharshak N, Hussein K, Geffen Y, Chowers Y, Geva-Zatorsky N, Paul M. Oral Capsulized Fecal Microbiota Transplantation for Eradication of Carbapenemase-producing Enterobacteriaceae Colonization With a Metagenomic Perspective. Clin Infect Dis 2021;73:e166-75. [PMID: 32511695 DOI: 10.1093/cid/ciaa737] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 16.0] [Reference Citation Analysis]
101 Marrs T, Walter J. Pros and cons: Is faecal microbiota transplantation a safe and efficient treatment option for gut dysbiosis? Allergy 2021;76:2312-7. [PMID: 33483999 DOI: 10.1111/all.14750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
102 Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124-47. [PMID: 34003176 DOI: 10.14309/ajg.0000000000001278] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 62.0] [Reference Citation Analysis]
103 Runge S, Rosshart SP. The Mammalian Metaorganism: A Holistic View on How Microbes of All Kingdoms and Niches Shape Local and Systemic Immunity. Front Immunol 2021;12:702378. [PMID: 34276696 DOI: 10.3389/fimmu.2021.702378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
104 Březina J, Bajer L, Wohl P, Ďuricová D, Hrabák P, Novotný A, Koželuhová J, Lukáš M, Mrázek J, Fliegerová KO, Kvasnová S, Chahrazed M, Mareš J, Špičák J, Drastich P. Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis-Results of a Randomized Controlled Trial. J Clin Med 2021;10:2753. [PMID: 34206663 DOI: 10.3390/jcm10132753] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
105 Mehta N, Wang T, Friedman-Moraco RJ, Carpentieri C, Mehta AK, Rouphael N, Dhere T, Larsen CP, Kraft CS, Woodworth MH. Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients. J Clin Microbiol 2021;:JCM0016121. [PMID: 34133889 DOI: 10.1128/JCM.00161-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Sanders DJ, Inniss S, Sebepos-Rogers G, Rahman FZ, Smith AM. The role of the microbiome in gastrointestinal inflammation. Biosci Rep 2021;41:BSR20203850. [PMID: 34076695 DOI: 10.1042/BSR20203850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
107 Goeser F, Sifft B, Stein-Thoeringer C, Farowski F, Strassburg CP, Brossart P, Higgins PG, Scheid C, Wolf D, Holderried TAW, Vehreschild MJGT, Cruz Aguilar MR. Fecal microbiota transfer for refractory intestinal graft-versus-host disease - Experience from two German tertiary centers. Eur J Haematol 2021;107:229-45. [PMID: 33934412 DOI: 10.1111/ejh.13642] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
108 Núñez F P, Quera R, Bay C, Thomson P. Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases. Gastroenterol Hepatol 2021:S0210-5705(21)00192-8. [PMID: 34118321 DOI: 10.1016/j.gastrohep.2021.05.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Torun A, Hupalowska A, Trzonkowski P, Kierkus J, Pyrzynska B. Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children. Front Immunol 2021;12:642166. [PMID: 34163468 DOI: 10.3389/fimmu.2021.642166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
110 Abad CLR, Safdar N. A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea. Gastroenterol Clin North Am 2021;50:323-40. [PMID: 34024444 DOI: 10.1016/j.gtc.2021.02.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
111 Gonzales-Luna AJ, Spinler JK, Oezguen N, Khan MAW, Danhof HA, Endres BT, Alam MJ, Begum K, Lancaster C, Costa GP, Savidge TC, Hurdle JG, Britton R, Garey KW. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe 2021;70:102387. [PMID: 34044101 DOI: 10.1016/j.anaerobe.2021.102387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
112 Malnick SDH, Fisher D, Somin M, Neuman MG. Treating the Metabolic Syndrome by Fecal Transplantation-Current Status. Biology (Basel) 2021;10:447. [PMID: 34065241 DOI: 10.3390/biology10050447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
113 Saeed M, Shoaib A, Kandimalla R, Javed S, Almatroudi A, Gupta R, Aqil F. Microbe-based therapies for colorectal cancer: Advantages and limitations. Semin Cancer Biol 2021:S1044-579X(21)00148-6. [PMID: 34020027 DOI: 10.1016/j.semcancer.2021.05.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
114 Scarpellini E, Scarcella L, Romanelli G, Basilico M, Lattanzi E, Rasetti C, Abenavoli L, Santori P. Nutritional Status and the Critically Ill Patient: Gut Microbiota and Immuno-Nutrition in I.C.U. at the Time of SARS-COV 2 Pandemic. Gastroenterology Insights 2021;12:259-69. [DOI: 10.3390/gastroent12020022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Madsen AMA, Halkjær SI, Christensen AH, Günther S, Browne PD, Kallemose T, Hansen LH, Petersen AM. The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study. Scand J Gastroenterol 2021;56:761-9. [PMID: 34000958 DOI: 10.1080/00365521.2021.1915375] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
116 Chaar A, Feuerstadt P. Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211011953. [PMID: 33995583 DOI: 10.1177/17562848211011953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 Dolle RE, Mcgrane LK, Janetka JW, Hammill JT, Guy RK, Debnath A, Cheuka PM, Manach CL, Chibale K, Elhammer A, Handfield M, Dawson MJ, Donadio S, Park JH, Joslyn A. Anti‐Infective Case Histories. Burger's Medicinal Chemistry and Drug Discovery 2021. [DOI: 10.1002/0471266949.bmc288] [Reference Citation Analysis]
118 Shin JH, Hays RA, Warren CA. Hospitalized Older Patients with Clostridioides difficile Infection Refractory to Conventional Antibiotic Therapy Benefit from Fecal Microbiota Transplant. Adv Geriatr Med Res 2021;3:e210012. [PMID: 34263258 DOI: 10.20900/agmr20210012] [Reference Citation Analysis]
119 Moreira-rosário A, Marques C, Pinheiro H, Araújo JR, Ribeiro P, Rocha R, Mota I, Pestana D, Ribeiro R, Pereira A, de Sousa MJ, Pereira-leal J, de Sousa J, Morais J, Teixeira D, Rocha JC, Silvestre M, Príncipe N, Gatta N, Amado J, Santos L, Maltez F, Boquinhas A, de Sousa G, Germano N, Sarmento G, Granja C, Póvoa P, Faria A, Calhau C. Gut microbiota diversity and C-Reactive Protein are predictors of disease severity in COVID-19 patients.. [DOI: 10.1101/2021.04.20.440658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Wilmanski T, Rappaport N, Diener C, Gibbons SM, Price ND. From taxonomy to metabolic output: what factors define gut microbiome health? Gut Microbes 2021;13:1-20. [PMID: 33890557 DOI: 10.1080/19490976.2021.1907270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
121 Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol 2021;14:17562848211009694. [PMID: 33959193 DOI: 10.1177/17562848211009694] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
122 Tadashi O. Current status, complications and prospects of fecal microbiota transplantation therapy. Arch Pathol Clin Res 2021;5:004-009. [DOI: 10.29328/journal.apcr.1001021] [Reference Citation Analysis]
123 Khanna S. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! J Intern Med 2021;290:294-309. [PMID: 33856727 DOI: 10.1111/joim.13290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
124 Björkqvist O, Rangel I, Serrander L, Magnusson C, Halfvarson J, Norén T, Bergman-Jungeström M. Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection. PLoS One 2021;16:e0249861. [PMID: 33836037 DOI: 10.1371/journal.pone.0249861] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
125 Cesario A, D'Oria M, Bove F, Privitera G, Boškoski I, Pedicino D, Boldrini L, Erra C, Loreti C, Liuzzo G, Crea F, Armuzzi A, Gasbarrini A, Calabresi P, Padua L, Costamagna G, Antonelli M, Valentini V, Auffray C, Scambia G. Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence. J Pers Med 2021;11:265. [PMID: 33918214 DOI: 10.3390/jpm11040265] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
126 Gweon TG, Na SY. Next Generation Fecal Microbiota Transplantation. Clin Endosc 2021;54:152-6. [PMID: 33761228 DOI: 10.5946/ce.2021.053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
127 Tixier EN, Verheyen E, Luo Y, Grinspan LT, Du CH, Ungaro RC, Walsh S, Grinspan AM. Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile. Dig Dis Sci 2021. [PMID: 33748913 DOI: 10.1007/s10620-021-06908-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
128 Guilfoyle J, Considine J, Bouchoucha SL. Faecal microbiota transplantation and the patient experience: A systematic review. J Clin Nurs 2021;30:1236-52. [PMID: 33377562 DOI: 10.1111/jocn.15625] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Al-Bakri AG, Akour AA, Al-Delaimy WK. Knowledge, attitudes, ethical and social perspectives towards fecal microbiota transplantation (FMT) among Jordanian healthcare providers. BMC Med Ethics 2021;22:19. [PMID: 33639935 DOI: 10.1186/s12910-021-00587-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
130 D Goldenberg S, Merrick B. The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection. Ther Adv Infect Dis 2021;8:2049936120981526. [PMID: 33614028 DOI: 10.1177/2049936120981526] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
131 Henson MA. Computational modeling of the gut microbiota reveals putative metabolic mechanisms of recurrent Clostridioides difficile infection. PLoS Comput Biol 2021;17:e1008782. [PMID: 33617526 DOI: 10.1371/journal.pcbi.1008782] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
132 Imdad A, Minkoff NZ, Tanner-smith EE, Zackular JP, Acra S, Nicholson MR. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile ). Cochrane Database of Systematic Reviews 2021. [DOI: 10.1002/14651858.cd013871] [Reference Citation Analysis]
133 Tariq R, Hayat M, Pardi D, Khanna S. Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2021;40:1383-92. [PMID: 33496893 DOI: 10.1007/s10096-021-04163-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
134 Khanna S. Advances in Clostridioides difficile therapeutics. Expert Rev Anti Infect Ther 2021;19:1067-70. [PMID: 33427531 DOI: 10.1080/14787210.2021.1874919] [Reference Citation Analysis]
135 Yoon H, Shim HI, Seol M, Shin CM, Park YS, Kim N, Lee DH. Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection. Gut Liver 2021;15:61-9. [PMID: 32839363 DOI: 10.5009/gnl20135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
136 Hays RA, Surawicz C. Clostridium (Now Clostridioides) difficile-Associated Disease. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_71] [Reference Citation Analysis]
137 Chau P-, Herring J. Body Ownership. Emergent Medicine and the Law 2021. [DOI: 10.1007/978-3-030-60208-6_5] [Reference Citation Analysis]
138 Reveles KR, Young EH, Zeidan AR, Dong Q. Microbiome changes in aging. Handbook of the Biology of Aging 2021. [DOI: 10.1016/b978-0-12-815962-0.00017-2] [Reference Citation Analysis]
139 Ossorio PN, Zhou Y. FMT and Microbial Medical Products: Generating High-Quality Evidence through Good Governance. J Law Med Ethics 2019;47:505-23. [DOI: 10.1177/1073110519897727] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
140 Nejadghaderi SA, Nazemalhosseini-Mojarad E, Asadzadeh Aghdaei H. Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy. Med Hypotheses 2021;147:110476. [PMID: 33482620 DOI: 10.1016/j.mehy.2020.110476] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
141 Abbasi A, Hajipour N, Hasannezhad P, Baghbanzadeh A, Aghebati-maleki L. Potential in vivo delivery routes of postbiotics. Critical Reviews in Food Science and Nutrition. [DOI: 10.1080/10408398.2020.1865260] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
142 Holster S, Repsilber D, Geng D, Hyötyläinen T, Salonen A, Lindqvist CM, Rajan SK, de Vos WM, Brummer RJ, König J. Correlations between microbiota and metabolites after faecal microbiota transfer in irritable bowel syndrome. Benef Microbes 2021;12:17-30. [PMID: 33350360 DOI: 10.3920/BM2020.0010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
143 Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol 2021;116:17-44. [DOI: 10.14309/ajg.0000000000001036] [Cited by in Crossref: 149] [Cited by in F6Publishing: 165] [Article Influence: 74.5] [Reference Citation Analysis]
144 Mehta SR, Yen EF. Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy. Transl Res 2021;230:197-207. [PMID: 33278650 DOI: 10.1016/j.trsl.2020.11.013] [Reference Citation Analysis]
145 Singh A, Mahajan R, Kao D, Midha V, Sood A. Long term management of ulcerative colitis with Faecal Microbiota Transplantation. Medicine in Microecology 2020;6:100026. [DOI: 10.1016/j.medmic.2020.100026] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
146 Cheng Y, Ling Z, Li L. The Intestinal Microbiota and Colorectal Cancer. Front Immunol 2020;11:615056. [PMID: 33329610 DOI: 10.3389/fimmu.2020.615056] [Cited by in Crossref: 86] [Cited by in F6Publishing: 96] [Article Influence: 43.0] [Reference Citation Analysis]
147 Baunwall SMD, Lee MM, Eriksen MK, Mullish BH, Marchesi JR, Dahlerup JF, Hvas CL. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine 2020;29-30:100642. [PMID: 33437951 DOI: 10.1016/j.eclinm.2020.100642] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 20.0] [Reference Citation Analysis]
148 Li N, Zuo B, Huang S, Zeng B, Han D, Li T, Liu T, Wu Z, Wei H, Zhao J, Wang J. Spatial heterogeneity of bacterial colonization across different gut segments following inter-species microbiota transplantation. Microbiome 2020;8:161. [PMID: 33208178 DOI: 10.1186/s40168-020-00917-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
149 Dahlman S, Avellaneda-Franco L, Barr JJ. Phages to shape the gut microbiota? Curr Opin Biotechnol 2021;68:89-95. [PMID: 33176253 DOI: 10.1016/j.copbio.2020.09.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
150 Scheeler A. Where Stool is a Drug: International Approaches to Regulating the use of Fecal Microbiota for Transplantation. J Law Med Ethics 2019;47:524-40. [PMID: 31957572 DOI: 10.1177/1073110519897729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
151 Holster S, Rode J, Bohr J, Kumawat AK, Veress G, Hultgren Hörnquist E, Brummer RJ, König J. Faecal microbiota transfer in patients with microscopic colitis - a pilot study in collagenous colitis. Scand J Gastroenterol 2020;55:1454-66. [PMID: 33142068 DOI: 10.1080/00365521.2020.1839544] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
152 Wen Q, Liu KJ, Cui BT, Li P, Wu X, Zhong M, Wei L, Tu H, Yuan Y, Lin D, Hsu WH, Wu DC, Yin H, Zhang FM. Impact of cap-assisted colonoscopy during transendoscopic enteral tubing: A randomized controlled trial. World J Gastroenterol 2020; 26(39): 6098-6110 [PMID: 33132658 DOI: 10.3748/wjg.v26.i39.6098] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
153 Steed DB, Wang T, Raheja D, Waldman AD, Babiker A, Dhere T, Kraft CS, Woodworth MH. Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. mSphere 2020;5:e00853-20. [PMID: 33055258 DOI: 10.1128/mSphere.00853-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
154 Haifer C, Leong RW, Paramsothy S. The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease. Curr Opin Pharmacol 2020;55:8-16. [PMID: 33035780 DOI: 10.1016/j.coph.2020.08.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
155 Limas Solano LM, Vargas Niño CE, Valbuena Rodríguez DC, Ramírez López LX. Trasplante de microbiota fecal: una revisión. Rev Colomb Gastroenterol 2020;35:229-337. [DOI: 10.22516/25007440.486] [Reference Citation Analysis]
156 Zellmer C, Sater MRA, Huntley MH, Osman M, Olesen SW, Ramakrishna B. Shiga Toxin–Producing Escherichia coli Transmission via Fecal Microbiota Transplant. Clinical Infectious Diseases 2021;72:e876-80. [DOI: 10.1093/cid/ciaa1486] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
157 Terveer EM, Vendrik KE, Ooijevaar RE, Lingen EV, Boeije-Koppenol E, Nood EV, Goorhuis A, Bauer MP, van Beurden YH, Dijkgraaf MG, Mulder CJ, Vandenbroucke-Grauls CM, Seegers JF, van Prehn J, Verspaget HW, Kuijper EJ, Keller JJ. Faecal microbiota transplantation for Clostridioides difficile infection: Four years' experience of the Netherlands Donor Feces Bank. United European Gastroenterol J 2020;8:1236-47. [PMID: 32990503 DOI: 10.1177/2050640620957765] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
158 Podlesny D, Fricke WF. Microbial Strain Engraftment, Persistence and Replacement after Fecal Microbiota Transplantation.. [DOI: 10.1101/2020.09.29.20203638] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
159 Saha S, Mara K, Pardi DS, Khanna S. Durability of Response to Fecal Microbiota Transplantation After Exposure to Risk Factors for Recurrence in Patients With Clostridioides difficile Infection. Clin Infect Dis 2021;73:e1706-12. [PMID: 32976567 DOI: 10.1093/cid/ciaa1457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
160 Cold F, Kousgaard SJ, Halkjaer SI, Petersen AM, Nielsen HL, Thorlacius-Ussing O, Hansen LH. Fecal Microbiota Transplantation in the Treatment of Chronic Pouchitis: A Systematic Review. Microorganisms 2020;8:E1433. [PMID: 32962069 DOI: 10.3390/microorganisms8091433] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
161 Tan P, Li X, Shen J, Feng Q. Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update. Front Pharmacol. 2020;11:574533. [PMID: 33041818 DOI: 10.3389/fphar.2020.574533] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 14.5] [Reference Citation Analysis]
162 Segal JP, Mullish BH, Quraishi MN, Iqbal T, Marchesi JR, Sokol H. Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. Therap Adv Gastroenterol 2020;13:1756284820946904. [PMID: 32952613 DOI: 10.1177/1756284820946904] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
163 Gulati M, Singh SK, Corrie L, Kaur IP, Chandwani L. Delivery routes for faecal microbiota transplants: Available, anticipated and aspired. Pharmacological Research 2020;159:104954. [DOI: 10.1016/j.phrs.2020.104954] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
164 Kwak S, Choi J, Hink T, Reske KA, Blount K, Jones C, Bost MH, Sun X, Burnham CD, Dubberke ER, Dantas G; CDC Prevention Epicenter Program. Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial. Microbiome 2020;8:125. [PMID: 32862830 DOI: 10.1186/s40168-020-00907-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
165 Alessandri G, Argentini C, Milani C, Turroni F, Cristina Ossiprandi M, van Sinderen D, Ventura M. Catching a glimpse of the bacterial gut community of companion animals: a canine and feline perspective. Microb Biotechnol 2020;13:1708-32. [PMID: 32864871 DOI: 10.1111/1751-7915.13656] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
166 Parfenov AL, Petrova MV, Pichugina IM, Luginina EV. Comorbidity Development in Patients with Severe Brain Injury Resulting in Chronic Critical Condition (Review). Obŝaâ reanimatologiâ 2020;16:72-89. [DOI: 10.15360/1813-9779-2020-4-72-89] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
167 Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Anderson R, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Care Cancer 2020;28:6129-43. [PMID: 32856210 DOI: 10.1007/s00520-020-05707-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
168 Gill M, Blacketer C, Chitti F, Telfer K, Papanicolas L, Dann LM, Tucker EC, Bryant RV, Costello SP. Physician and patient perceptions of fecal microbiota transplant for recurrent or refractory Clostridioides difficile in the first 6 years of a central stool bank. JGH Open 2020;4:950-7. [PMID: 33102769 DOI: 10.1002/jgh3.12396] [Reference Citation Analysis]
169 Holster S, Lindqvist CM, Repsilber D, Salonen A, de Vos WM, König J, Brummer RJ. The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study. Clin Transl Gastroenterol 2019;10:e00034. [PMID: 31009405 DOI: 10.14309/ctg.0000000000000034] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 24.5] [Reference Citation Analysis]
170 Mańkowska-Wierzbicka D, Stelmach-Mardas M, Gabryel M, Tomczak H, Skrzypczak-Zielińska M, Zakerska-Banaszak O, Sowińska A, Mahadea D, Baturo A, Wolko Ł, Słomski R, Dobrowolska A. The Effectiveness of Multi-Session FMT Treatment in Active Ulcerative Colitis Patients: A Pilot Study. Biomedicines 2020;8:E268. [PMID: 32756350 DOI: 10.3390/biomedicines8080268] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
171 Ianiro G, Segal JP, Mullish BH, Quraishi MN, Porcari S, Fabiani G, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders. Future Microbiol 2020;15:1173-83. [PMID: 32954843 DOI: 10.2217/fmb-2020-0061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
172 Barberio B, Facchin S, Mele E, D'Incà R, Sturniolo GC, Farinati F, Zingone F, Quagliariello A, Ghisa M, Massimi D, Casadei C, Savarino EV. Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital. Therap Adv Gastroenterol 2020;13:1756284820934315. [PMID: 32774464 DOI: 10.1177/1756284820934315] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
173 Galloway-Peña JR, Jenq RR. The only thing that stops a bad microbiome, is a good microbiome. Haematologica 2019;104:1511-3. [PMID: 31366464 DOI: 10.3324/haematol.2019.222430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
174 Subramaniam CB, Bowen JM, Gladman MA, Lustberg MB, Mayo SJ, Wardill HR. The microbiota-gut-brain axis: An emerging therapeutic target in chemotherapy-induced cognitive impairment. Neurosci Biobehav Rev 2020;116:470-9. [PMID: 32681936 DOI: 10.1016/j.neubiorev.2020.07.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
175 Ryu AJ, Rahimi RS, Leise MD. The Current Hepatic Encephalopathy Pipeline. J Clin Exp Hepatol 2020;10:377-85. [PMID: 32655239 DOI: 10.1016/j.jceh.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
176 Akobeng AK, Singh P, Kumar M, Al Khodor S. Role of the gut microbiota in the pathogenesis of coeliac disease and potential therapeutic implications. Eur J Nutr 2020;59:3369-90. [PMID: 32651763 DOI: 10.1007/s00394-020-02324-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
177 Kashtanova DA, Tkacheva ON. The phenomenon of intestinal permeability and its association with cardiovascular disease. Current status. Cardiovasc Ther Prev 2020;19:2474. [DOI: 10.15829/1728-8800-2020-2474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
178 Bermejo Boixareu C, Tutor-ureta P, Ramos Martínez A. Actualización sobre infección por Clostridium difficile en el paciente mayor. Revista Española de Geriatría y Gerontología 2020;55:225-235. [DOI: 10.1016/j.regg.2019.12.003] [Reference Citation Analysis]
179 Abdali ZI, Roberts TE, Barton P, Hawkey PM. Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent Clostridioides difficile infection. EClinicalMedicine 2020;24:100420. [PMID: 32637898 DOI: 10.1016/j.eclinm.2020.100420] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
180 Duquenoy A, Bellais S, Gasc C, Schwintner C, Dore J, Thomas V. Assessment of Gram- and Viability-Staining Methods for Quantifying Bacterial Community Dynamics Using Flow Cytometry. Front Microbiol 2020;11:1469. [PMID: 32676069 DOI: 10.3389/fmicb.2020.01469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
181 Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Autenrieth IB, Vehreschild MJGT, Jazmati N, Gerhard M, Stein-Thoeringer CK, Rupp J, Ulm K, Ott A, Lasch F, Koch A, Manns MP, Suerbaum S, Bachmann O. Microbiota-associated risk factors for C. difficile acquisition in hospitalized patients: A prospective, multicentric study. Clin Infect Dis 2020:ciaa871. [PMID: 32589701 DOI: 10.1093/cid/ciaa871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
182 Basson AR, Zhou Y, Seo B, Rodriguez-Palacios A, Cominelli F. Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease. Transl Res 2020;226:1-11. [PMID: 32585148 DOI: 10.1016/j.trsl.2020.05.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
183 Bibbò S, Settanni CR, Porcari S, Bocchino E, Ianiro G, Cammarota G, Gasbarrini A. Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. J Clin Med 2020;9:E1757. [PMID: 32517023 DOI: 10.3390/jcm9061757] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
184 Amoroso C, Perillo F, Strati F, Fantini MC, Caprioli F, Facciotti F. The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation. Cells 2020;9:E1234. [PMID: 32429359 DOI: 10.3390/cells9051234] [Cited by in Crossref: 55] [Cited by in F6Publishing: 65] [Article Influence: 27.5] [Reference Citation Analysis]
185 Cotter JM, Nicholson MR, Kociolek LK. An Infectious Diseases Perspective on Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children. J Pediatric Infect Dis Soc 2019;8:580-4. [PMID: 31550348 DOI: 10.1093/jpids/piz062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
186 Haifer C, Kelly CR, Paramsothy S, Andresen D, Papanicolas LE, McKew GL, Borody TJ, Kamm M, Costello SP, Andrews JM, Begun J, Chan HT, Connor S, Ghaly S, Johnson PD, Lemberg DA, Paramsothy R, Redmond A, Sheorey H, van der Poorten D, Leong RW. Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. Gut 2020;69:801-10. [PMID: 32047093 DOI: 10.1136/gutjnl-2019-320260] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 14.5] [Reference Citation Analysis]
187 Le Roy T, Aron-wisnewsky J, Clément K. Le transfert de microbiote fécal : quel potentiel thérapeutique dans le traitement des maladies métaboliques ? Nutrition Clinique et Métabolisme 2020;34:108-115. [DOI: 10.1016/j.nupar.2019.12.001] [Reference Citation Analysis]
188 Soo WT, Bryant RV, Costello SP. Faecal microbiota transplantation: indications, evidence and safety. Aust Prescr 2020;43:36-8. [PMID: 32346208 DOI: 10.18773/austprescr.2020.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
189 Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillilä M, Punkkinen J, Koskenpato J, Anttila V, Tillonen J, Satokari R, Arkkila P. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther 2020;51:1321-31. [DOI: 10.1111/apt.15740] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 20.0] [Reference Citation Analysis]
190 Teng T, Gao F, He W, Fu H, Guo J, Bai G, Shi B. An Early Fecal Microbiota Transfer Improves the Intestinal Conditions on Microflora and Immunoglobulin and Antimicrobial Peptides in Piglets. J Agric Food Chem 2020;68:4830-43. [PMID: 32252520 DOI: 10.1021/acs.jafc.0c00545] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
191 Fadda HM. The Route to Palatable Fecal Microbiota Transplantation. AAPS PharmSciTech 2020;21:114. [PMID: 32296975 DOI: 10.1208/s12249-020-1637-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
192 Leonardi I, Paramsothy S, Doron I, Semon A, Kaakoush NO, Clemente JC, Faith JJ, Borody TJ, Mitchell HM, Colombel JF, Kamm MA, Iliev ID. Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. Cell Host Microbe 2020;27:823-829.e3. [PMID: 32298656 DOI: 10.1016/j.chom.2020.03.006] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 35.0] [Reference Citation Analysis]
193 Kousgaard SJ, Michaelsen TY, Nielsen HL, Kirk KF, Brandt J, Albertsen M, Thorlacius-Ussing O. Clinical results and microbiota changes after faecal microbiota transplantation for chronic pouchitis: a pilot study. Scand J Gastroenterol 2020;55:421-9. [PMID: 32285709 DOI: 10.1080/00365521.2020.1748221] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
194 Stallmach A, Steube A, Grunert P, Hartmann M, Biehl LM, Vehreschild MJGT. Fecal Microbiota Transfer. Dtsch Arztebl Int 2020;117:31-8. [PMID: 32031511 DOI: 10.3238/arztebl.2020.0031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
195 Henson MA. Computational Modeling of the Gut Microbiota Predicts Metabolic Mechanisms of Recurrent Clostridioides difficile Infection.. [DOI: 10.1101/2020.04.10.036111] [Reference Citation Analysis]
196 Voth E, Khanna S. Fecal microbiota transplantation for treatment of patients with recurrent Clostridioides difficile infection. Expert Rev Anti Infect Ther 2020;18:669-76. [PMID: 32266848 DOI: 10.1080/14787210.2020.1752192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
197 Raffals LE. Self-administered Fecal Microbial Transplants—What Could Possibly Go Wrong? Crohn's & Colitis 360 2020;2. [DOI: 10.1093/crocol/otaa025] [Reference Citation Analysis]
198 Cho JM, Pardi DS, Khanna S. Update on Treatment of Clostridioides difficile Infection. Mayo Clinic Proceedings 2020;95:758-69. [DOI: 10.1016/j.mayocp.2019.08.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
199 Bauer CM, Zhang X, Long MD, Sandler RS. Characteristics of Fecal Microbiota Transplantation Use in Inflammatory Bowel Disease Cohort. Crohn's & Colitis 360 2020;2. [DOI: 10.1093/crocol/otaa024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
200 Antushevich H. Fecal microbiota transplantation in disease therapy. Clinica Chimica Acta 2020;503:90-8. [DOI: 10.1016/j.cca.2019.12.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 23.0] [Reference Citation Analysis]
201 Sullivan MH, Boggiano VL, Smith KL. Management of difficult-to-treat Clostridioides difficile in a patient with chronic osteomyelitis. BMJ Case Rep 2020;13:e233095. [PMID: 32229549 DOI: 10.1136/bcr-2019-233095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Kukla M, Adrych K, Dobrowolska A, Mach T, Reguła J, Rydzewska G. Guidelines for Clostridium difficile infection in adults. Prz Gastroenterol 2020;15:1-21. [PMID: 32215122 DOI: 10.5114/pg.2020.93629] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
203 Gurram B, Sue PK. Fecal microbiota transplantation in children: current concepts. Curr Opin Pediatr 2019;31:623-9. [PMID: 31169545 DOI: 10.1097/MOP.0000000000000787] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
204 Oami T, Chihade DB, Coopersmith CM. The microbiome and nutrition in critical illness. Curr Opin Crit Care 2019;25:145-9. [PMID: 30855323 DOI: 10.1097/MCC.0000000000000582] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
205 Mikail M, O'doherty KC, Poutanen SM, Hota SS. Ethical implications of recruiting universal stool donors for faecal microbiota transplantation. The Lancet Infectious Diseases 2020;20:e44-9. [DOI: 10.1016/s1473-3099(19)30569-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
206 Gupta A, Saha S, Khanna S. Therapies to modulate gut microbiota: Past, present and future. World J Gastroenterol 2020; 26(8): 777-788 [PMID: 32148376 DOI: 10.3748/wjg.v26.i8.777] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 35] [Article Influence: 17.5] [Reference Citation Analysis]
207 Lopetuso LR, Ianiro G, Allegretti JR, Bibbò S, Gasbarrini A, Scaldaferri F, Cammarota G. Fecal transplantation for ulcerative colitis: current evidence and future applications. Expert Opin Biol Ther 2020;20:343-51. [PMID: 32083498 DOI: 10.1080/14712598.2020.1733964] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
208 Bouza E, Aguado JM, Alcalá L, Almirante B, Alonso-Fernández P, Borges M, Cobo J, Guardiola J, Horcajada JP, Maseda E, Mensa J, Merchante N, Muñoz P, Pérez Sáenz JL, Pujol M, Reigadas E, Salavert M, Barberán J. Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR). Rev Esp Quimioter 2020;33:151-75. [PMID: 32080996 DOI: 10.37201/req/2065.2020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
209 Luo Y, Tixier EN, Grinspan AM. Fecal Microbiota Transplantation for Clostridioides difficile in High-Risk Older Adults Is Associated with Early Recurrence. Dig Dis Sci 2020;65:3647-51. [PMID: 32078714 DOI: 10.1007/s10620-020-06147-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
210 Cerquetella M, Rossi G, Suchodolski JS, Schmitz SS, Allenspach K, Rodríguez-Franco F, Furlanello T, Gavazza A, Marchegiani A, Unterer S, Burgener IA, Pengo G, Jergens AE. Proposal for rational antibacterial use in the diagnosis and treatment of dogs with chronic diarrhoea. J Small Anim Pract 2020;61:211-5. [PMID: 32065388 DOI: 10.1111/jsap.13122] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
211 Maraolo AE, Scotto R, Zappulo E, Pinchera B, Schiano Moriello N, Nappa S, Buonomo AR, Gentile I. Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. Expert Rev Anti Infect Ther 2020;18:191-202. [PMID: 32011191 DOI: 10.1080/14787210.2020.1725473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
212 Fitzgibbon G, Mills KHG. The microbiota and immune-mediated diseases: Opportunities for therapeutic intervention. Eur J Immunol 2020;50:326-37. [PMID: 31991477 DOI: 10.1002/eji.201948322] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
213 Zhen S, Zhao C, Zhao X, Ji W, Li J. Faecal Microbiota Microsphere Contributed to Relieving Gut Barrier Damage in Colitis. Macromol Res 2020;28:644-9. [DOI: 10.1007/s13233-020-8078-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Mullish BH, Quraishi MN, Segal JP, Ianiro G, Iqbal TH. The gut microbiome: what every gastroenterologist needs to know. Frontline Gastroenterol 2021;12:118-27. [PMID: 33613943 DOI: 10.1136/flgastro-2019-101376] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
215 Xu R, Wan J, Lin C, Su Y. Effects of Early Intervention with Antibiotics and Maternal Fecal Microbiota on Transcriptomic Profiling Ileal Mucusa in Neonatal Pigs. Antibiotics (Basel) 2020;9:E35. [PMID: 31963653 DOI: 10.3390/antibiotics9010035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
216 Kachlíková M, Sabaka P, Koščálová A, Bendžala M, Dovalová Z, Stankovič I. Comorbid status and the faecal microbial transplantation failure in treatment of recurrent Clostridioides difficile infection - pilot prospective observational cohort study. BMC Infect Dis 2020;20:52. [PMID: 31948404 DOI: 10.1186/s12879-020-4773-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
217 Papanicolas LE, Gordon DL, Wesselingh SL, Rogers GB. Improving Risk-Benefit in Faecal Transplantation through Microbiome Screening. Trends Microbiol 2020;28:331-9. [PMID: 31952909 DOI: 10.1016/j.tim.2019.12.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
218 Antonelli M, Martin-Loeches I, Dimopoulos G, Gasbarrini A, Vallecoccia MS. Clostridioides difficile (formerly Clostridium difficile) infection in the critically ill: an expert statement. Intensive Care Med 2020;46:215-24. [PMID: 31938827 DOI: 10.1007/s00134-019-05873-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
219 Ortigão R, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D. Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. GE Port J Gastroenterol 2020;27:336-51. [PMID: 32999906 DOI: 10.1159/000505036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
220 Chen X, Li HY, Hu XM, Zhang Y, Zhang SY. Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure. Chin Med J (Engl) 2019;132:1843-55. [PMID: 31306229 DOI: 10.1097/CM9.0000000000000330] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
221 Xiang Q, Wu X, Pan Y, Wang L, Cui C, Guo Y, Zhu L, Peng J, Wei H. Early-Life Intervention Using Fecal Microbiota Combined with Probiotics Promotes Gut Microbiota Maturation, Regulates Immune System Development, and Alleviates Weaning Stress in Piglets. Int J Mol Sci 2020;21:E503. [PMID: 31941102 DOI: 10.3390/ijms21020503] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
222 Sinclair HA, Chapman P. Faecal microbiota transplantation: a review. Microbiol Aust 2020;41:65. [DOI: 10.1071/ma20019] [Reference Citation Analysis]
223 Saha S, Khanna S. C. difficile Infection and Antibiotic Associated Diarrhea. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.11069-4] [Reference Citation Analysis]
224 Hays RA, Surawicz C. Clostridium (Now Clostridioides) difficile-Associated Disease. Geriatric Gastroenterology 2020. [DOI: 10.1007/978-3-319-90761-1_71-1] [Reference Citation Analysis]
225 Sasidharan S, Divakar K, Saudagar P. Culture-Independent Omics-Techniques for Microbiome-Based Molecular Therapeutics Against Infectious Diseases. Metagenomic Systems Biology 2020. [DOI: 10.1007/978-981-15-8562-3_5] [Reference Citation Analysis]
226 Reigadas E, Bouza E, Olmedo M, Vázquez-Cuesta S, Villar-Gómara L, Alcalá L, Marín M, Rodríguez-Fernández S, Valerio M, Muñoz P. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules. J Hosp Infect 2020;105:319-24. [PMID: 31883938 DOI: 10.1016/j.jhin.2019.12.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
227 Costello SP, Bryant RV. Faecal microbiota transplantation in Australia: bogged down in regulatory uncertainty. Intern Med J 2019;49:148-51. [PMID: 30754077 DOI: 10.1111/imj.14212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
228 Oksi J, Anttila VJ, Mattila E. Treatment of Clostridioides (Clostridium) difficile infection. Ann Med 2020;52:12-20. [PMID: 31801387 DOI: 10.1080/07853890.2019.1701703] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
229 Cammarota G, Ianiro G, Kelly CR, Mullish BH, Allegretti JR, Kassam Z, Putignani L, Fischer M, Keller JJ, Costello SP, Sokol H, Kump P, Satokari R, Kahn SA, Kao D, Arkkila P, Kuijper EJ, Vehreschild MJG, Pintus C, Lopetuso L, Masucci L, Scaldaferri F, Terveer EM, Nieuwdorp M, López-Sanromán A, Kupcinskas J, Hart A, Tilg H, Gasbarrini A. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 2019;68:2111-21. [PMID: 31563878 DOI: 10.1136/gutjnl-2019-319548] [Cited by in Crossref: 177] [Cited by in F6Publishing: 188] [Article Influence: 59.0] [Reference Citation Analysis]
230 Tamilarasan AG, Irving P, Meadows CI, Goldenberg S. Faecal microbiota transplantation for refractory C lostridium difficile infection. BMJ Case Rep 2019;12:e231027. [PMID: 31780599 DOI: 10.1136/bcr-2019-231027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
231 Quraishi MN, Shaheen W, Oo YH, Iqbal TH. Immunological Mechanisms Underpinning Faecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. Clin Exp Immunol. 2019;199:24-38. [PMID: 31777058 DOI: 10.1111/cei.13397] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
232 Yalchin M, Segal JP, Mullish BH, Quraishi MN, Iqbal TH, Marchesi JR, Hart AL. Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease. Therap Adv Gastroenterol. 2019;12:1756284819891038. [PMID: 31803254 DOI: 10.1177/1756284819891038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
233 Freitag TL, Hartikainen A, Jouhten H, Sahl C, Meri S, Anttila VJ, Mattila E, Arkkila P, Jalanka J, Satokari R. Minor Effect of Antibiotic Pre-treatment on the Engraftment of Donor Microbiota in Fecal Transplantation in Mice. Front Microbiol 2019;10:2685. [PMID: 31824463 DOI: 10.3389/fmicb.2019.02685] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
234 Kumar V, Fischer M. Expert opinion on fecal microbiota transplantation for the treatment of Clostridioides difficile infection and beyond. Expert Opin Biol Ther. 2020;20:73-81. [PMID: 31690143 DOI: 10.1080/14712598.2020.1689952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
235 Alhifany AA, Almutairi AR, Almangour TA, Shahbar AN, Abraham I, Alessa M, Alnezary FS, Cheema E. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials. BMJ Open 2019;9:e031145. [PMID: 31699731 DOI: 10.1136/bmjopen-2019-031145] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
236 Tixier EN, Verheyen E, Ungaro RC, Grinspan AM. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther 2019;50:1094-9. [PMID: 31612528 DOI: 10.1111/apt.15526] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
237 Duvallet C, Zellmer C, Panchal P, Budree S, Osman M, Alm EJ. Framework for rational donor selection in fecal microbiota transplant clinical trials. PLoS One 2019;14:e0222881. [PMID: 31600222 DOI: 10.1371/journal.pone.0222881] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
238 Holster S, Hooiveld GJ, Repsilber D, Vos WM, Brummer RJ, König J. Allogenic Faecal Microbiota Transfer Induces Immune-Related Gene Sets in the Colon Mucosa of Patients with Irritable Bowel Syndrome. Biomolecules 2019;9:E586. [PMID: 31597320 DOI: 10.3390/biom9100586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
239 Lin TC, Hung YP, Ko WC, Ruan JW. Fecal microbiota transplantation for Clostridium difficile infection in Taiwan: Establishment and implementation. J Microbiol Immunol Infect 2019;52:841-50. [PMID: 31607571 DOI: 10.1016/j.jmii.2019.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
240 Dougé A, Bay JO, Ravinet A, Scanzi J. [Intestinal microbiota and allogeneic stem cell transplantation]. Bull Cancer 2020;107:72-83. [PMID: 31582175 DOI: 10.1016/j.bulcan.2019.08.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
241 Zhang Z, Mocanu V, Cai C, Dang J, Slater L, Deehan EC, Walter J, Madsen KL. Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome-A Systematic Review.Nutrients. 2019;11. [PMID: 31557953 DOI: 10.3390/nu11102291] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 30.0] [Reference Citation Analysis]
242 Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore D, Colville A, Bhala N, Iqbal TH, Settle C, Kontkowski G, Hart AL, Hawkey PM, Williams HR, Goldenberg SD. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. J Hosp Infect. 2018;100 Suppl 1:S1-S31. [PMID: 30173851 DOI: 10.1016/j.jhin.2018.07.037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
243 Yoon YK, Suh JW, Kang EJ, Kim JY. Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyond Clostridioides difficile infection. Ann Med 2019;51:379-89. [PMID: 31468999 DOI: 10.1080/07853890.2019.1662477] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
244 Oliphant K, Parreira VR, Cochrane K, Allen-Vercoe E. Drivers of human gut microbial community assembly: coadaptation, determinism and stochasticity. ISME J 2019;13:3080-92. [PMID: 31477821 DOI: 10.1038/s41396-019-0498-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
245 Tan X, Johnson S. Fecal microbiota transplantation (FMT) for C. difficile infection, just say 'No'. Anaerobe 2019;60:102092. [PMID: 31472233 DOI: 10.1016/j.anaerobe.2019.102092] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
246 Allegretti JR, Mullish BH, Kelly C, Fischer M. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet. 2019;394:420-431. [PMID: 31379333 DOI: 10.1016/s0140-6736(19)31266-8] [Cited by in Crossref: 158] [Cited by in F6Publishing: 163] [Article Influence: 52.7] [Reference Citation Analysis]
247 Krajicek E, Bohm M, Sagi S, Fischer M. Fulminant Clostridium difficile Infection Cured by Fecal Microbiota Transplantation in a Bone Marrow Transplant Recipient With Critical Neutropenia. ACG Case Rep J 2019;6:e00198. [PMID: 31737727 DOI: 10.14309/crj.0000000000000198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
248 Pitta MR, Campos FM, Monteiro AG, Cunha AGF, Porto JD, Gomes RR. Tutorial on Diarrhea and Enteral Nutrition: A Comprehensive Step-By-Step Approach. JPEN J Parenter Enteral Nutr 2019;43:1008-19. [PMID: 31544264 DOI: 10.1002/jpen.1674] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
249 Wang C, Li Q, Ren J. Microbiota-Immune Interaction in the Pathogenesis of Gut-Derived Infection. Front Immunol. 2019;10:1873. [PMID: 31456801 DOI: 10.3389/fimmu.2019.01873] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 17.0] [Reference Citation Analysis]
250 Duvallet C, Zellmer C, Panchal P, Budree S, Osman M, Alm E. Framework for rational donor selection in fecal microbiota transplant clinical trials.. [DOI: 10.1101/19000307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
251 Nowak A, Hedenstierna M, Ursing J, Lidman C, Nowak P. Efficacy of Routine Fecal Microbiota Transplantation for Treatment of Recurrent Clostridium difficile Infection: A Retrospective Cohort Study. Int J Microbiol 2019;2019:7395127. [PMID: 31354831 DOI: 10.1155/2019/7395127] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
252 Kelly CR, Fischer M, Grinspan A, Allegretti JR. Patients Eligible for Trials of Microbe-Based Therapeutics Do Not Represent the Population With Recurrent Clostridioides difficile Infection. Clin Gastroenterol Hepatol 2020;18:1099-101. [PMID: 31254675 DOI: 10.1016/j.cgh.2019.06.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
253 Aron-wisnewsky J, Clément K, Nieuwdorp M. Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? Curr Diab Rep 2019;19. [DOI: 10.1007/s11892-019-1180-z] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 18.3] [Reference Citation Analysis]
254 Wortelboer K, Nieuwdorp M, Herrema H. Fecal microbiota transplantation beyond Clostridioides difficile infections. EBioMedicine 2019;44:716-29. [PMID: 31201141 DOI: 10.1016/j.ebiom.2019.05.066] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 21.0] [Reference Citation Analysis]
255 Singh T, Bedi P, Bumrah K, Singh J, Rai M, Seelam S. Updates in Treatment of Recurrent Clostridium difficile Infection. J Clin Med Res. 2019;11:465-471. [PMID: 31236163 DOI: 10.14740/jocmr3854] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
256 Borody TJ, Eslick GD, Clancy RL. Fecal microbiota transplantation as a new therapy: from Clostridioides difficile infection to inflammatory bowel disease, irritable bowel syndrome, and colon cancer. Curr Opin Pharmacol. 2019;49:43-51. [PMID: 31173991 DOI: 10.1016/j.coph.2019.04.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
257 Wong AC, Levy M. New Approaches to Microbiome-Based Therapies. mSystems 2019;4:e00122-19. [PMID: 31164406 DOI: 10.1128/mSystems.00122-19] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 16.3] [Reference Citation Analysis]
258 Oneto C, Feuerstadt P. Concise Commentary: Treatment of Recurrent C. difficile Infection: A New Take on the Fecal-Oral Route. Dig Dis Sci 2019;64:1679. [PMID: 30762209 DOI: 10.1007/s10620-019-05498-6] [Reference Citation Analysis]
259 Kalinkovich A, Livshits G. A cross talk between dysbiosis and gut-associated immune system governs the development of inflammatory arthropathies. Semin Arthritis Rheum 2019;49:474-84. [PMID: 31208713 DOI: 10.1016/j.semarthrit.2019.05.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
260 Rokkas T, Gisbert JP, Gasbarrini A, Hold GL, Tilg H, Malfertheiner P, Megraud F, O'Morain C. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection. United European Gastroenterol J 2019;7:1051-63. [PMID: 31662862 DOI: 10.1177/2050640619854587] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
261 McSweeney B, Allegretti JR, Fischer M, Xu H, Goodman KJ, Monaghan T, McLeod C, Mullish BH, Petrof EO, Phelps EL, Chis R, Edmison A, Juby A, Ennis-Davis R, Roach B, Wong K, Kao D. In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation. Gut Microbes 2020;11:51-62. [PMID: 31122134 DOI: 10.1080/19490976.2019.1611153] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
262 Dailey FE, Turse EP, Daglilar E, Tahan V. The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications. Curr Opin Pharmacol. 2019;49:29-33. [PMID: 31103793 DOI: 10.1016/j.coph.2019.04.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 15.3] [Reference Citation Analysis]
263 Song JH, Kim YS. Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention. Gut Liver 2019;13:16-24. [PMID: 30400734 DOI: 10.5009/gnl18071] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 15.0] [Reference Citation Analysis]
264 Rombey T, Panagiotopoulou IG, Hind D, Fearnhead NS. Preoperative bowel stimulation prior to ileostomy closure to restore bowel function more quickly and improve postoperative outcomes: a systematic review. Colorectal Dis 2019;21:994-1003. [PMID: 30963659 DOI: 10.1111/codi.14636] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
265 Saha S, Khanna S. Management of Clostridioides difficile colitis: insights for the gastroenterologist. Therap Adv Gastroenterol 2019;12:1756284819847651. [PMID: 31105766 DOI: 10.1177/1756284819847651] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
266 Nicholson MR, Mitchell PD, Alexander E, Ballal S, Bartlett M, Becker P, Davidovics Z, Docktor M, Dole M, Felix G, Gisser J, Hourigan SK, Jensen MK, Kaplan JL, Kelsen J, Kennedy M, Khanna S, Knackstedt E, Leier M, Lewis J, Lodarek A, Michail S, Oliva-Hemker M, Patton T, Queliza K, Russell GH, Singh N, Solomon A, Suskind DL, Werlin S, Kellermayer R, Kahn SA. Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children. Clin Gastroenterol Hepatol 2020;18:612-619.e1. [PMID: 31009795 DOI: 10.1016/j.cgh.2019.04.037] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
267 Saha S, Tariq R, Tosh PK, Pardi DS, Khanna S. Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: a systematic review. Clin Microbiol Infect. 2019;25:958-963. [PMID: 30986562 DOI: 10.1016/j.cmi.2019.04.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 17.3] [Reference Citation Analysis]
268 Abu-Sbeih H, Choi K, Tran CN, Wang X, Lum P, Shuttlesworth G, Stroehlein JR, Okhuysen PC, Wang Y. Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients. Eur J Gastroenterol Hepatol 2019;31:128-34. [PMID: 30339561 DOI: 10.1097/MEG.0000000000001288] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
269 Hibbard J, Jiang Z, Dupont H. Fecal calprotectin and fecal indole predict outcome of fecal microbiota transplantation in subjects with recurrent Clostridium difficile infection. Anaerobe 2019;56:102-5. [DOI: 10.1016/j.anaerobe.2019.03.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
270 Wardill HR, Secombe KR, Bryant RV, Hazenberg MD, Costello SP. Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients. EBioMedicine 2019;44:730-40. [PMID: 30940601 DOI: 10.1016/j.ebiom.2019.03.070] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
271 Tavoukjian V. Faecal microbiota transplantation for the decolonization of antibiotic-resistant bacteria in the gut: a systematic review and meta-analysis. J Hosp Infect 2019;102:174-88. [PMID: 30926290 DOI: 10.1016/j.jhin.2019.03.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
272 Kim KO, Gluck M. Fecal Microbiota Transplantation: An Update on Clinical Practice. Clin Endosc. 2019;52:137-143. [PMID: 30909689 DOI: 10.5946/ce.2019.009] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 28.0] [Reference Citation Analysis]
273 Peri R, Aguilar RC, Tüffers K, Erhardt A, Link A, Ehlermann P, Angeli W, Frank T, Storr M, Glück T, Sturm A, Rosien U, Tacke F, Bachmann O, Solbach P, Stallmach A, Goeser F, Vehreschild MJ; German Clinical Microbiome Study Group (GCMSG). The impact of technical and clinical factors on fecal microbiota transfer outcomes for the treatment of recurrent Clostridioides difficile infections in Germany. United European Gastroenterol J 2019;7:716-22. [PMID: 31210950 DOI: 10.1177/2050640619839918] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
274 Cammarota G, Gallo A, Ianiro G, Montalto M. Emerging drugs for the treatment of clostridium difficile. Expert Opin Emerg Drugs 2019;24:17-28. [PMID: 30841760 DOI: 10.1080/14728214.2019.1591371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
275 Otani S, Coopersmith CM. Gut integrity in critical illness. J Intensive Care 2019;7:17. [PMID: 30923621 DOI: 10.1186/s40560-019-0372-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 18.0] [Reference Citation Analysis]
276 Nishida A, Imaeda H, Inatomi O, Bamba S, Sugimoto M, Andoh A. The efficacy of fecal microbiota transplantation for patients with chronic pouchitis: A case series. Clin Case Rep 2019;7:782-8. [PMID: 30997086 DOI: 10.1002/ccr3.2096] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
277 Kanai T. 1) Microbiota and Gastrointestinal Diseases. J Jpn Soc Intern Med 2019;108:401-407. [DOI: 10.2169/naika.108.401] [Reference Citation Analysis]
278 Chen C, Chen Y, Liou J, Wu M; for the Taiwan Gastrointestinal Disease and Helicobacter Consortium. From germ theory to germ therapy. Kaohsiung J Med Sci 2019;35:73-82. [DOI: 10.1002/kjm2.12011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
279 Benavent Boladeras R, Ariño Blasco S. Transplante fecal en geriatría. Revista Española de Geriatría y Gerontología 2019;54:119-120. [DOI: 10.1016/j.regg.2018.10.005] [Reference Citation Analysis]
280 Mcilroy JR, Segal JP, Mullish BH, Nabil Quraishi M, Gasbarrini A, Cammarota G, Ianiro G. Current and future targets for faecal microbiota transplantation. Human Microbiome Journal 2019;11:100045. [DOI: 10.1016/j.humic.2018.08.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
281 Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, Abu-Zidan FM, Ansaloni L, Augustin G, Bala M, Ben-Ishay O, Biffl WL, Brecher SM, Camacho-Ortiz A, Caínzos MA, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cortese F, Cui Y, Czepiel J, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckmann C, Eiland EH, Forrester JD, Fraga GP, Frossard JL, Fry DE, Galeiras R, Ghnnam W, Gomes CA, Griffiths EA, Guirao X, Ahmed MH, Herzog T, Kim JI, Iqbal T, Isik A, Itani KMF, Labricciosa FM, Lee YY, Juang P, Karamarkovic A, Kim PK, Kluger Y, Leppaniemi A, Lohsiriwat V, Machain GM, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Ordoñez CA, Pagani L, Petrosillo N, Portela F, Rasa K, Rems M, Sakakushev BE, Segovia-Lohse H, Sganga G, Shelat VG, Spigaglia P, Tattevin P, Tranà C, Urbánek L, Ulrych J, Viale P, Baiocchi GL, Catena F. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg 2019;14:8. [PMID: 30858872 DOI: 10.1186/s13017-019-0228-3] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 22.7] [Reference Citation Analysis]
282 Farowski F, Solbach P, Tsakmaklis A, Brodesser S, Cruz Aguilar MR, Cornely OA, Dettmer K, Higgins PG, Suerbaum S, Jazmati N, Oefner PJ, Vehreschild MJGT; German Clinical Microbiome Study Group (GCMSG). Potential biomarkers to predict outcome of faecal microbiota transfer for recurrent Clostridioides difficile infection. Dig Liver Dis 2019;51:944-51. [PMID: 30770201 DOI: 10.1016/j.dld.2019.01.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
283 Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13:193-204. [PMID: 30791767 DOI: 10.1080/17474124.2019.1569513] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 16.0] [Reference Citation Analysis]
284 Hui W, Li T, Liu W, Zhou C, Gao F. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis. PLoS One. 2019;14:e0210016. [PMID: 30673716 DOI: 10.1371/journal.pone.0210016] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 25.0] [Reference Citation Analysis]
285 Wilson BC, Vatanen T, Cutfield WS, O'Sullivan JM. The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front Cell Infect Microbiol. 2019;9:2. [PMID: 30719428 DOI: 10.3389/fcimb.2019.00002] [Cited by in Crossref: 173] [Cited by in F6Publishing: 187] [Article Influence: 57.7] [Reference Citation Analysis]
286 Lai CY, Sung J, Cheng F, Tang W, Wong SH, Chan PKS, Kamm MA, Sung JJY, Kaplan G, Chan FKL, Ng SC. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment Pharmacol Ther. 2019;49:354-363. [PMID: 30628108 DOI: 10.1111/apt.15116] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 18.0] [Reference Citation Analysis]
287 Reygner J, Kapel N. Current Status of Fecal Microbiota Transplantation. Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications 2019. [DOI: 10.1016/b978-0-12-815249-2.00016-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
288 Borody T. Fecal Microbiota Transplantation. Gastrointestinal Diseases and their Associated Infections 2019. [DOI: 10.1016/b978-0-323-54843-4.00018-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
289 Surana NK. The microbiota and infectious diseases. Genomic and Precision Medicine 2019. [DOI: 10.1016/b978-0-12-801496-7.00023-x] [Reference Citation Analysis]
290 Otani S, Chihade DB, Coopersmith CM. Critical illness and the role of the microbiome. Acute Med Surg 2019;6:91-4. [PMID: 30976432 DOI: 10.1002/ams2.383] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
291 Greenberg SA, Youngster I, Cohen NA, Livovsky DM, Strahilevitz J, Israeli E, Melzer E, Paz K, Fliss-Isakov N, Maharshak N. Five years of fecal microbiota transplantation - an update of the Israeli experience. World J Gastroenterol 2018; 24(47): 5403-5414 [PMID: 30598584 DOI: 10.3748/wjg.v24.i47.5403] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
292 Oliphant K, Parreira VR, Cochrane K, Allen-vercoe E. Drivers of human gut microbial community assembly: Coadaptation, determinism and stochasticity.. [DOI: 10.1101/501940] [Reference Citation Analysis]
293 Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, Petersen AM. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut 2018;67:2107-15. [PMID: 29980607 DOI: 10.1136/gutjnl-2018-316434] [Cited by in Crossref: 169] [Cited by in F6Publishing: 179] [Article Influence: 42.3] [Reference Citation Analysis]
294 Bulow C, Langdon A, Hink T, Wallace M, Reske KA, Patel S, Sun X, Seiler S, Jones S, Kwon JH, Burnham CA, Dantas G, Dubberke ER. Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential. mSphere 2018;3:e00588-18. [PMID: 30463925 DOI: 10.1128/mSphereDirect.00588-18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
295 Ramai D, Zakhia K, Ofosu A, Ofori E, Reddy M. Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness. Ann Gastroenterol 2019;32:30-8. [PMID: 30598589 DOI: 10.20524/aog.2018.0328] [Cited by in Crossref: 15] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
296 Sun X, Jia Z. Microbiome modulates intestinal homeostasis against inflammatory diseases. Vet Immunol Immunopathol 2018;205:97-105. [PMID: 30459007 DOI: 10.1016/j.vetimm.2018.10.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
297 Jiang ZD, Jenq RR, Ajami NJ, Petrosino JF, Alexander AA, Ke S, Iqbal T, DuPont AW, Muldrew K, Shi Y, Peterson C, Do KA, DuPont HL. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial. PLoS One 2018;13:e0205064. [PMID: 30388112 DOI: 10.1371/journal.pone.0205064] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 12.3] [Reference Citation Analysis]
298 Savelkoul EH, Pathmakanthan S, Hawkey P, Iqbal TH. Manipulating gut microbiota using faecal microbiome transplantation: update on evidence and guide for use. Gastrointestinal Nursing 2018;16:43-49. [DOI: 10.12968/gasn.2018.16.9.43] [Reference Citation Analysis]
299 Xie W, Yang X, Xia HH, He X. Fecal Microbiota Transplantation for Treating Hepatic Encephalopathy: Experimental and Clinical Evidence and Possible Underlying Mechanisms. Journal of Exploratory Research in Pharmacology 2018;3:105-110. [DOI: 10.14218/jerp.2018.00017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
300 Khan MY, Dirweesh A, Khurshid T, Siddiqui WJ. Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology 2018;30:1309-17. [DOI: 10.1097/meg.0000000000001243] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
301 Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore DJ, Colville A, Bhala N, Iqbal TH, Settle C, Kontkowski G, Hart AL, Hawkey PM, Goldenberg SD, Williams HRT. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 2018;67:1920-41. [PMID: 30154172 DOI: 10.1136/gutjnl-2018-316818] [Cited by in Crossref: 166] [Cited by in F6Publishing: 172] [Article Influence: 41.5] [Reference Citation Analysis]
302 Kim P, Gadani A, Abdul-Baki H, Mitre R, Mitre M. Fecal microbiota transplantation in recurrent Clostridium difficile infection: A retrospective single-center chart review. JGH Open 2019;3:4-9. [PMID: 30834334 DOI: 10.1002/jgh3.12093] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
303 Naghibi MM, Day R. Microbiota and infection prevention: making space for probiotics in healthcare. Gastrointestinal Nursing 2018;16:28-34. [DOI: 10.12968/gasn.2018.16.8.28] [Reference Citation Analysis]
304 Mullish B, Quraishi M, Segal J, Williams H, Goldenberg S. Introduction to the joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) faecal microbiota transplant guidelines. Journal of Hospital Infection 2018;100:130-2. [DOI: 10.1016/j.jhin.2018.07.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
305 Martinez C, Edwards J, Hassoun A. Commercialized fecal microbiota transplantation provides efficacious treatment of Clostridium difficile infection. Infect Dis (Lond) 2018;50:864-7. [PMID: 30265170 DOI: 10.1080/23744235.2018.1500709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
306 Krajicek E, Fischer M, Allegretti JR, Kelly CR. Nuts and Bolts of Fecal Microbiota Transplantation. Clin Gastroenterol Hepatol 2019;17:345-52. [PMID: 30268564 DOI: 10.1016/j.cgh.2018.09.029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
307 Major G, Bradshaw L, Boota N, Sprange K, Diggle M, Montgomery A, Jawhari A, Spiller RC; RAPID Collaboration Group. Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial. Gut 2019;68:1224-31. [PMID: 30254135 DOI: 10.1136/gutjnl-2018-316794] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
308 Mcilroy JR, Nalagatla N, Hansen R, Hart A, Hold GL. Faecal microbiota transplantation as a treatment for inflammatory bowel disease: a national survey of adult and paediatric gastroenterologists in the UK. Frontline Gastroenterol 2018;9:250-5. [PMID: 30245786 DOI: 10.1136/flgastro-2017-100936] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
309 Denton C, Price A, Friend J, Manithody C, Blomenkamp K, Westrich M, Kakarla V, Phillips W, Krebs J, Abraham Munoz S, Osei H, Jain AK. Role of the Gut⁻Liver Axis in Driving Parenteral Nutrition-Associated Injury. Children (Basel) 2018;5:E136. [PMID: 30257520 DOI: 10.3390/children5100136] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
310 Bouri S, Hart A. Fecal microbial transplantation: an update. Current Opinion in Clinical Nutrition & Metabolic Care 2018;21:405-10. [DOI: 10.1097/mco.0000000000000488] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
311 Gagliardi A, Totino V, Cacciotti F, Iebba V, Neroni B, Bonfiglio G, Trancassini M, Passariello C, Pantanella F, Schippa S. Rebuilding the Gut Microbiota Ecosystem. Int J Environ Res Public Health 2018;15:E1679. [PMID: 30087270 DOI: 10.3390/ijerph15081679] [Cited by in Crossref: 155] [Cited by in F6Publishing: 164] [Article Influence: 38.8] [Reference Citation Analysis]
312 Daliri EB, Tango CN, Lee BH, Oh D. Human microbiome restoration and safety. International Journal of Medical Microbiology 2018;308:487-97. [DOI: 10.1016/j.ijmm.2018.05.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
313 Baktash A, Terveer EM, Zwittink RD, Hornung BVH, Corver J, Kuijper EJ, Smits WK. Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections. Front Microbiol 2018;9:1242. [PMID: 29946308 DOI: 10.3389/fmicb.2018.01242] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 12.8] [Reference Citation Analysis]
314 Ianiro G, Maida M, Burisch J, Simonelli C, Hold G, Ventimiglia M, Gasbarrini A, Cammarota G. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and meta-analysis. United European Gastroenterol J. 2018;6:1232-1244. [PMID: 30288286 DOI: 10.1177/2050640618780762] [Cited by in Crossref: 104] [Cited by in F6Publishing: 107] [Article Influence: 26.0] [Reference Citation Analysis]
315 Ianiro G, Masucci L, Quaranta G, Simonelli C, Lopetuso LR, Sanguinetti M, Gasbarrini A, Cammarota G. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther. 2018;48:152-159. [PMID: 29851107 DOI: 10.1111/apt.14816] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 20.5] [Reference Citation Analysis]
316 Ooijevaar R, van Beurden Y, Terveer E, Goorhuis A, Bauer M, Keller J, Mulder C, Kuijper E. Update of treatment algorithms for Clostridium difficile infection. Clinical Microbiology and Infection 2018;24:452-62. [DOI: 10.1016/j.cmi.2017.12.022] [Cited by in Crossref: 76] [Cited by in F6Publishing: 60] [Article Influence: 19.0] [Reference Citation Analysis]
317 Saha S, Khanna S. Microbiota replacement for Clostridium difficile by capsule is as effective as via colonoscopy. J Thorac Dis. 2018;10:S1081-S1083. [PMID: 29849203 DOI: 10.21037/jtd.2018.04.18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
318 Panchal P, Budree S, Scheeler A, Medina G, Seng M, Wong WF, Eliott R, Mitchell T, Kassam Z, Allegretti JR, Osman M. Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0619-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
319 Goldenberg SD, Batra R, Beales I, Digby-Bell JL, Irving PM, Kellingray L, Narbad A, Franslem-Elumogo N. Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review. Infect Dis Ther. 2018;7:71-86. [PMID: 29450831 DOI: 10.1007/s40121-018-0189-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
320 Samarkos M, Mastrogianni E, Kampouropoulou O. The role of gut microbiota in Clostridium difficile infection. Eur J Intern Med 2018;50:28-32. [PMID: 29428498 DOI: 10.1016/j.ejim.2018.02.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 9.5] [Reference Citation Analysis]
321 Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11:1-10. [PMID: 29285689 DOI: 10.1007/s12328-017-0813-5] [Cited by in Crossref: 533] [Cited by in F6Publishing: 458] [Article Influence: 106.6] [Reference Citation Analysis]
322 Camacho-Ortiz A, Gutiérrez-Delgado EM, Garcia-Mazcorro JF, Mendoza-Olazarán S, Martínez-Meléndez A, Palau-Davila L, Baines SD, Maldonado-Garza H, Garza-González E. Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome. PLoS One 2017;12:e0189768. [PMID: 29261736 DOI: 10.1371/journal.pone.0189768] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
323 Jalanka J, Hillamaa A, Satokari R, Mattila E, Anttila V, Arkkila P. The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2018;47:371-9. [DOI: 10.1111/apt.14443] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
324 NIHR Dissemination Centre. Faecal transplant effectively treats recurrent or unresponsive Clostridium difficile. 2017. [DOI: 10.3310/signal-000506] [Reference Citation Analysis]
325 Louis P. Different Substrate Preferences Help Closely Related Bacteria To Coexist in the Gut. mBio 2017;8:e01824-17. [PMID: 29114031 DOI: 10.1128/mBio.01824-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
326 Kump P, Wurm P, Gröchenig HP, Wenzl H, Petritsch W, Halwachs B, Wagner M, Stadlbauer V, Eherer A, Hoffmann KM, Deutschmann A, Reicht G, Reiter L, Slawitsch P, Gorkiewicz G, Högenauer C. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther 2018;47:67-77. [PMID: 29052237 DOI: 10.1111/apt.14387] [Cited by in Crossref: 102] [Cited by in F6Publishing: 106] [Article Influence: 20.4] [Reference Citation Analysis]